Pfizer to Acquire Pyxis Oncology

TL;DR

Pfizer buying Pyxis Oncology, deal expected H1 2025.

AI Summary

Pyxis Oncology, Inc. announced on February 4, 2025, that it has entered into a definitive agreement to be acquired by Pfizer Inc. The transaction is expected to close in the first half of 2025, subject to customary closing conditions. This acquisition aims to strengthen Pfizer's oncology portfolio.

Why It Matters

This acquisition by a major pharmaceutical company like Pfizer could significantly impact the development and availability of Pyxis Oncology's pipeline assets.

Risk Assessment

Risk Level: medium — The acquisition is subject to closing conditions, and the integration process could present challenges.

Key Players & Entities

• Pyxis Oncology, Inc. (company) — Company filing the report and being acquired
• Pfizer Inc. (company) — Acquiring company
• February 04, 2025 (date) — Date of the report and announcement
• first half of 2025 (date) — Expected closing period for the acquisition

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share PYXS The Nasdaq Global Se

Filing Documents

• pyxs-20250204.htm (8-K) — 46KB
• pyxs-ex99_1.htm (EX-99.1) — 31KB
• img244827169_0.jpg (GRAPHIC) — 24KB
• 0000950170-25-012846.txt ( ) — 232KB
• pyxs-20250204.xsd (EX-101.SCH) — 25KB
• pyxs-20250204_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. On February 4, 2025, Pyxis Oncology, Inc. issued a press release announcing the initiation of a Phase 1/2 combination trial, PYX-201-102, with PYX-201 and Merck's Keytruda (pembrolizumab) in multiple solid tumors. In addition, the Part 2 monotherapy expansion cohorts of the ongoing Phase 1 PYX-201-101 study have begun enrolling patients. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Forward Looking Statements

Forward Looking Statements This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements are often identified by the use of words such as "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "likely," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "should," "to be," "will," "would," or the negative or plural of these words, or similar expressions or variations, although not all forward-looking statements contain these words. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified herein, and those discussed in the section titled "Risk Factors" set forth in Part II, Item 1A. of the Company's Quarterly Report on Form 10-Q filed with SEC on November 12, 2024, and our other filings, each of which is on file with the Securities and Exchange Commission. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date hereof and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated February 4, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Pyxis Oncology, Inc. Date: February 4, 2025 By: /s/ Pamela Connealy Pamela Connealy Chief Financial Officer and Chief Operating Officer